News
HBIO
6.05
-1.63%
-0.10
Weekly Report: what happened at HBIO last week (0622-0626)?
Weekly Report · 3d ago
Weekly Report: what happened at HBIO last week (0615-0619)?
Weekly Report · 06/22 10:18
Harvard Bioscience management to meet with KeyBanc
TipRanks · 06/16 19:35
Weekly Report: what happened at HBIO last week (0608-0612)?
Weekly Report · 06/15 10:20
Weekly Report: what happened at HBIO last week (0601-0605)?
Weekly Report · 06/08 10:15
Harvard Bioscience Shareholders Expand Equity Plans, Elect Directors
TipRanks · 06/02 21:51
Harvard Bioscience shareholders approve amended 2021 incentive plan share increase at annual meeting
PUBT · 06/02 20:02
Weekly Report: what happened at HBIO last week (0525-0529)?
Weekly Report · 06/01 10:20
Lensar Appoints Michael A. Rossi As Interim CFO Effective May 29, 2026
Benzinga · 05/29 20:09
LENSAR names Michael Rossi interim CFO effective May 29
PUBT · 05/29 20:07
Weekly Report: what happened at HBIO last week (0518-0522)?
Weekly Report · 05/25 10:23
Harvard Bioscience Balances Margin Gains With Soft Sales
TipRanks · 05/20 02:06
Weekly Report: what happened at HBIO last week (0511-0515)?
Weekly Report · 05/18 10:23
Harvard Bioscience Earnings Call Highlights Gradual Recovery
TipRanks · 05/13 00:23
Harvard Bioscience reports Q1 adjusted EPS (33c) vs. ($1.25) last year
TipRanks · 05/12 14:05
Harvard Bioscience reiterates Q2 revenue view $20.5M-$22.5M
TipRanks · 05/12 13:59
Harvard Bioscience reaffirms FY26 revenue growth of 2%-4%
TipRanks · 05/12 13:45
Harvard Bioscience reaffirms 2026 outlook for 2%-4% revenue growth as Project Viking targets $4M annual savings
Seeking Alpha · 05/12 13:33
Harvard Bioscience Unveils Strategic Transformation Toward Translational Tools
TipRanks · 05/12 12:44
Harvard Bioscience Q1 2026 Earnings Call Transcript
Benzinga · 05/12 12:38
More
Webull provides a variety of real-time HBIO stock news. You can receive the latest news about Harvard Biosci through multiple platforms. This information may help you make smarter investment decisions.
About HBIO
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.